News | Contrast Media | February 15, 2023

Requiring half the gadolinium dosage compared to other macrocyclic gadolinium-based contrast agents (GBCAs) in approved indications in the U.S., gadopiclenol also has the highest relaxivity compared to approved GBCAs1-7

Requiring half the gadolinium dosage compared to other macrocyclic gadolinium-based contrast agents (GBCAs) in approved indications in the U.S., gadopiclenol also has the highest relaxivity compared to approved GBCAs1-7

February 15, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announced today that Wellstar Health System is among the first establishments in the nation to trial VUEWAY (gadopiclenol) injection, a recently FDA-approved macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). Gadopiclenol needs only half the dose compared to other GBCAs in approved indications in the U.S. to accomplish the same image clarity due to the fact that it has the highest relaxivity of all GBCAs compared to approved GBCAs.1-7

"We are honored to stand alongside these prestigious leaders of the medical community for the first VUEWAY injections, after FDA approval," said Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging. "We're particularly excited about our innovations in contrast imaging because of the wide-reaching impact across disease categories with 30 million MRI scans conducted annually, globally.8 That these institutions have prioritized offering VUEWAY injection, a novel next-generation MRI contrast agent, reinforces the potential value VUEWAY injection will provide in patient care and diagnostics."

VUEWAY (gadopiclenol) injection received FDA approval on Sept. 21, 2022, for use with MRI in adults and pediatric patients aged two years and older to detect and visualize lesions in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).7

Two recent Phase III trials sharing similar methodologies and endpoints demonstrate the efficacy and safety of gadopiclenol in MRI of the CNS (the PICTURE trial) and of the body (the PROMISE trial). Combining study populations, over 500 individuals had MRI scans compared when done with gadopiclenol at half the dose of a conventional agent, gadobutrol, at full dose. Even with the lower dosage, blinded readers rated gadopiclenol scans as having comparable image quality.9-11

VUEWAY injection is manufactured in the U.S. by Liebel-Flarsheim Company LLC in Raleigh, NC. VUEWAY injection is approved for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging (MRI) of the CNS ((brain, spine, and surrounding tissues) and the body (head and neck, thorax, abdomen, pelvis and musculoskeletal system).7 

For more information: www.vueway.com

References:

1 Robic C, Port M, Rousseaux O, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate with High T1 Relaxivity. Invest Radiol 2019; 54: 475-484.
2 GADAVIST® (gadobutrol) Injection. Full Prescribing Information.  Bayer HealthCare Pharmaceuticals Inc. Whippany, NJ; April 2022.
3 DOTAREM® (gadoterate meglumine) Injection. Full Prescribing Information. Guerbet LLC. Princeton, NJ. April 2022.
4 CLARISCAN™ (gadoterate meglumine) injection for intravenous use. Full Prescribing Information. GE Healthcare. Chicago, IL; February 2020.
5 ProHance® (Gadoteridol) Injection. Full Prescribing Information and Patient Medication Guide. Monroe Twp., NJ: Bracco Diagnostics Inc.; June 2022.
6 MultiHance® (gadobenate dimeglumine) Injection. Full Prescribing Information and Patient Medication Guide. Monroe Twp., NJ: Bracco Diagnostics Inc.; August 2018.
7 Vueway™ (gadopiclenol) Injection Full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; September 2022.
8 Lohrke J, et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther. 2016 Jan;33(1):1-28.
9 Loevner L, Kolumban B, Hutoczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System. The PICTURE Randomized Clinical Trial. Invest Radiol. 2022 Dec.
10 Clinical Study Report of Study GDX-44-010. Data on file.
11 Clinical Study Report of Study GDX-44-011. Data on file.

 

Related Content of MRI Gadolinium Concerns

AJR Publishes Best Practices for Iodinated Contrast Media Shortage

Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

 

Related Content: 

Efficacy and Safety of Gadopiclenol with Contrast-enhanced MRI of the Central Nervous System Published

Guerbet Announces FDA Approval of Elucirem (Gadopiclenol) for Use in Contrast-enhanced MRI 

Contrast Media Supply Shortage: How and What Now? 

FDA Grants Import Discretion of Bracco’s Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages 

Guerbet to Spotlight the Novel New Drug Elucirem (gadopiclenol) injection at RSNA22 


Related Content

News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | Artificial Intelligence

December 5, 2023 — Radiology is under severe economic pressure as reimbursement rates fall for many common scans. At the ...

Time December 05, 2023
arrow
News | Artificial Intelligence

December 5, 2023 — Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro, the next-generation AI software for brain ...

Time December 05, 2023
arrow
News | RSNA

December 1, 2023 — Royal Philips, a global leader in health technology, put patients and healthcare providers center ...

Time December 01, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
News | Radiology Imaging

November 30, 2023 — Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the ...

Time November 30, 2023
arrow
News | Pediatric Imaging

November 30, 2023 — Youth baseball players are prone to elbow pain and injuries, including repetitive overuse changes ...

Time November 30, 2023
arrow
News | Contrast Media

November 29, 2023 — Bayer continues to advance its comprehensive Radiology portfolio with progress in the development ...

Time November 29, 2023
arrow
News | Pediatric Imaging

November 29, 2023 — Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and ...

Time November 29, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

November 29, 2023 — Researchers have identified objective evidence of how the neck muscles are involved in primary ...

Time November 29, 2023
arrow
Subscribe Now